Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report

INTRODUCTION: In about 15% to 20% of breast cancer cases, human epidermal growth factor receptor 2 (HER2) over-expression or gene-amplification is associated with poor prognosis. Thanks to the development of target therapies, HER2 positive patients can be managed using HER2-targeting drugs. There ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Li, Wentao, Liu, Xin, Zhang, Jingjing, Huang, Xiaoyan, Zhang, Na, Fu, Tonghui, Ma, Dalin, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
3500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748359/
https://www.ncbi.nlm.nih.gov/pubmed/33371069
http://dx.doi.org/10.1097/MD.0000000000023406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748359/
https://www.ncbi.nlm.nih.gov/pubmed/33371069
http://dx.doi.org/10.1097/MD.0000000000023406

Ejemplares similares